The medication is commonly used to provide supportive relief during acute symptomatic episodes arising from vascular headache disorders. The combination is applied in contexts where additional symptomatic support is needed for managing acute episodes of migraine headaches and cluster headache. The medication is relevant in clinical settings that involve acute or temporary symptom patterns, and the key benefit is that it may assist with managing the attack by helping to ease the symptom load once the severe manifestations have begun.

---

Managing Accompanying Symptom Clusters

The medication helps address symptom clusters that may become intense or disruptive, focusing on symptoms that create noticeable physiological strain alongside pain. This includes managing symptoms related to heightened physiological activity, such as light sensitivity (photophobia) and noise sensitivity (phonophobia), and is relevant for easing the associated symptoms of nausea and vomiting. The medication provides support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of heightened symptoms.

“Applied in contexts where additional symptomatic support is needed.”

---

Quick Fact: Symptom Support

Use Context	Symptom Focus	Severity Targeted
Acute Treatment	Throbbing Head Pain	Moderate to Severe
Symptom Support	Nausea, Photophobia	Hard-to-Tolerate

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Ergotamine/Caffeine

Official regulatory documents define strict eligibility rules for Ergotamine and Caffeine, primarily based on vascular health, organ function, and reproductive status. The medicine is approved for use in adults for the acute treatment of severe vascular headaches.

Use is absolutely contraindicated in several populations to prevent severe vasospasm and potential ischemic events.

Eligibility Status	Key Populations/Conditions
Allowed Population	Adults (approved for acute vascular headaches).
Contraindicated	Pregnant women (Category X), Patients with Coronary Artery Disease or Peripheral Vascular Disease, Uncontrolled Hypertension, Sepsis, and Known Hypersensitivity.
Strictly Prohibited	Impaired Hepatic Function, Impaired Renal Function, and Concomitant use with potent CYP 3A4 inhibitors or other Triptans.
Not Established/Recommended	Pediatric Population (safety/efficacy not established), Geriatric Population (insufficient data), and Chronic Daily Administration.

Eligibility is defined by regulatory bodies to manage the risks associated with the drug's powerful vascular effects, limiting its use to eligible adults and prohibiting it in patients with underlying metabolic or cardiovascular vulnerabilities.

Ergotamine, an ergot alkaloid, can cause serious drug interactions, primarily due to its vasoconstrictive properties and its metabolism through the Cytochrome P450 (CYP) 3A4 enzyme system in the liver. Inhibition of this enzyme can lead to dangerously high levels of ergotamine in the bloodstream, increasing the risk of severe vasospasm, a condition known as ergotism.

---

Contraindicated Medications (Avoid Use)

The simultaneous use of ergotamine with certain drugs is contraindicated and should be strictly avoided due to the potential for life-threatening complications, including cerebral ischemia, peripheral ischemia, and gangrene. These medications include:

• Potent CYP3A4 Inhibitors: This group includes certain HIV protease inhibitors (e.g., ritonavir, nelfinavir, indinavir) and macrolide antibiotics (e.g., erythromycin, clarithromycin, troleandomycin), as well as some antifungals (e.g., ketoconazole, itraconazole).
• Other Vasoconstrictors: Combining ergotamine with other strong vasoconstrictors can lead to additive blood vessel constriction. This includes other ergot-type drugs (e.g., dihydroergotamine) and triptans (e.g., sumatriptan, rizatriptan). A separation of at least 24 hours is typically required between the use of ergotamine and a triptan. Additionally, use with sympathomimetics (e.g., pseudoephedrine) and beta-blockers (e.g., propranolol) should be monitored closely.

---

Other Interactions

Grapefruit juice can also inhibit the CYP3A4 enzyme and should be avoided. Nicotine from smoking or other tobacco products may also increase the risk of adverse vasoconstrictive effects.

Modulation of Cranial Vascular Tone and Neural Pathways

Ergotamine's core mechanism involves functioning as a partial agonist at specific serotonin receptors, primarily 5-HT1 B and 5-HT1 D, as well as alpha-adrenergic receptors. The 5-HT1 B and alpha-receptor activation directly causes contraction of the smooth muscle in cranial blood vessels. Concurrently, 5-HT1 D activation inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings. This dual activity modulates the cranial vascular tone and influences the neurogenic inflammation pathway.

Mechanistic Synergy via Absorption Kinetics

The combination with Caffeine introduces a significant mechanism of absorption enhancement, increasing the rate at which Ergotamine is delivered to its central and peripheral targets. Caffeine itself acts as a non-selective adenosine receptor antagonist, contributing a mild, complementary mechanism of vasoconstriction. This synergy promotes a higher rate of Ergotamine delivery to its targets, resulting in a more rapid engagement of the 5-HT and alpha-adrenergic receptor mechanisms.

Mechanistic Constraints and Non-Selectivity

The drug's non-selective agonist profile across multiple receptor families (including alpha-adrenergic and D2) inherently results in a more generalized systemic vasoconstriction, which is not confined to the cranial circulation. Furthermore, the mechanism is subject to physiological constraints where established vascular changes may become less responsive to receptor-mediated modulation.

Ergotamine combined with Caffeine is administered exclusively for the acute, intermittent treatment of vascular headaches and is prohibited for chronic daily use. This strict requirement to avoid continuous administration establishes the core temporal pattern of usage.

---

Administration Routes and Dosing

The medication is available for oral administration as a 1 mg Ergotamine / 100 mg Caffeine tablet and for rectal administration as a 2 mg Ergotamine / 100 mg Caffeine suppository. Administration should commence at the first sign of the attack.

Dosage Form	Initial Dose	Repetition Pattern	Maximum Dose
Oral Tablet	2 tablets	1 tablet every 30 minutes, as needed	6 tablets per attack / 10 tablets per week
Rectal Suppository	1 suppository	1 suppository after 1 hour, if needed	2 suppositories per attack / 5 suppositories per week

These dosing rules define the required titration strategy for an acute event while setting firm limits on intake. The total dose of ergotamine administered must not exceed the specified weekly maximum to maintain the integrity of the use protocol.

---

Contextual Constraints

In addition to timing, the use of this medicine includes specific contextual constraints. Consumption of grapefruit or grapefruit juice is avoided during the administration period. Furthermore, the drug is not administered to patients with severe hepatic or renal impairment, which is a key non-use principle for these populations. The safety and efficacy of the drug have not been established for pediatric populations.

Ergotamine: Recent Clinical Evidence

This overview describes the types of clinical studies that research examined for Ergotamine, focusing only on how the evidence has been gathered and what research gaps exist.

---

Evidence for Acute Treatment of Migraine and Cluster Headache

Research explored Ergotamine/Caffeine as a drug used in research exploring how symptoms change over time during acute headache events. This evidence base consists of historical Randomized Controlled Trials (RCTs), where the drug was studied for acute symptom relief in patients, alongside modern systematic reviews that aggregate and analyze the older data. The research evaluated patients experiencing conditions associated with acute or disruptive episodes, specifically migraine attacks characterized as moderate to severe.

In these research scenarios, studies monitored outcomes related to physical discomfort, primarily measuring how individuals reported the reduction of headache pain, often referred to as "headache relief." They also tracked the achievement of complete pain freedom at specific intervals, typically 1 to 2 hours after administration. Findings describe patterns observed in the studies regarding measurements of pain outcomes, as well as the tracking of outcomes related to accompanying symptoms, such as light and noise sensitivity.

---

Long-term Follow-up and Durability of Response

Given that Ergotamine was studied for conditions involving periods of heightened symptoms (acute attacks), the primary focus of the research was observed in short timeframes (hours). Researchers closely monitored the sustained response to see if the initial pain relief lasted, tracking patients for 24 to 48 hours post-dose. This research provides context but not individual predictions about the durability of the effect.

Long-term effects are not fully established through dedicated efficacy trials. Data regarding long-term outcomes and chronic, high-frequency use are mainly derived from observational data rather than dedicated efficacy trials. There is limited information for long-term outcomes regarding the medication's use in standard efficacy contexts.

---

What the Research Landscape Shows About Uncertainty and Gaps

The principal limitation is that the core evidence base for the medication's evaluation is largely historical, and the original studies often employed designs that are not considered standard today. Evidence quality varies across studies due to differing methodologies and endpoints used decades ago. Furthermore, data show patterns related to high variability in patient response. Follow-up durations were limited in the key acute efficacy trials. This means that while studies contribute to the broader evidence landscape, contemporary, comparative evidence is limited for many aspects of the drug’s use.

Common questions about Ergotamine (FAQ)

---

Q: What is Ergotamine used for?

Ergotamine is a medication indicated for the acute treatment of migraine attacks with or without aura, and for the acute treatment of cluster headaches. It is not generally intended for the prevention of these types of headaches.

Q: How quickly does Ergotamine start to work?

The onset of action for ergotamine may vary among individuals. It is typically intended to be taken as soon as symptoms of a headache begin. The specific timeline of relief can differ based on the individual and the dosage form.

Q: Is Ergotamine safe to take every day?

The label information for ergotamine emphasizes that it should not be used daily or for extended periods. Overuse of ergotamine-containing medications may lead to a condition known as medication-overuse headache (rebound headache), and may increase the risk of serious side effects.

Q: What are the potential side effects of Ergotamine?

Like all medications, ergotamine can cause side effects. Common side effects may include nausea, vomiting, dizziness, and localized tingling sensations. Serious, though rare, side effects involve vascular issues like vasospasm, which is a narrowing of the blood vessels. A healthcare provider can discuss a complete list of potential side effects and warnings.

Q: Can I take Ergotamine if I am pregnant or breastfeeding?

Ergotamine is generally not recommended for use during pregnancy due to potential risks. It may also pass into breast milk and is generally advised against during breastfeeding. It is important to discuss all treatment options and risks with a healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

Official Storage and Disposal Instructions for Ergotamine

Ergotamine must be stored at controlled room temperature, typically 20 C to 25 C. It is crucial to not refrigerate or freeze the medication. To maintain stability, the drug must be protected from light and moisture and kept in its original container with the lid tightly closed.

All ergotamine must be stored out of the sight and reach of children.

Disposal Requirements

Do not flush ergotamine down the toilet or discard it into wastewater. Unused or expired medication should be disposed of through a drug take-back program. If one is unavailable, mix the product with an undesirable substance like dirt or cat litter, seal it in a container or bag, and place it in the trash.